上海凯利泰医疗科技股份有限公司 二、监事会对公司 2024 年度有关事项的意见 2024 年度监事会工作报告 2024 年，上海凯利泰医疗科技股份有限公司（以下简称"公司"）监事会严 格按照《公司法》、《公司章程》、《深圳证券交易所上市公司自律监管指引第 2 号-创业板上市公司规范运作指引》、《监事会议事规则》等有关法律法规及公司 内控制度的要求，从切实维护公司利益和广大股东权益出发，认真履行了监督职 责。监事会成员通过列席董事会和股东大会会议，对重大决策事项进行监督，对 公司财务状况及董事、高管人员履职情况进行监督，确保公司能够规范、有序的 运作。现将监事会在报告期内的工作情况报告如下： | | | 会议时间 | | 会议名 | 审议内容 | | | --- | --- | --- | --- | --- | --- | --- | | | | | | 称 | | | | | 2024 | 年 | 4 | 第五届 监事会第十 | | 1、《关于子公司实施股权激励暨放弃优先认 | | 月 1 | 日 | | | | 购权的议案》 | | | | | | | 三次会议 | | | | | | | | | 1、《 ...

独立董事候选人声明与承诺 声明人刘学文作为上海凯利泰医疗科技股份有限公司 第六届董事会独立董事候选人，已充分了解并同意由提名 人上海凯诚君泰投资有限公司提名为上海凯利泰医疗科技 股份有限公司（以下简称"公司"）第六届董事会独立董 事候选人。现公开声明和保证，本人与该公司之间不存在 任何影响本人独立性的关系，且符合相关法律、行政法规、 部门规章、规范性文件和深圳证券交易所业务规则对独立 董事候选人任职资格及独立性的要求，具体声明如下： 一、已经通过上海凯利泰医疗科技股份有限公司第六 届董事会提名委员会资格审查，提名人与本人不存在利害 关系或者其他可能影响独立履职情形的密切关系。 □ 是 ☑ 否 如否，请详细说明：由上海凯诚君泰投资有限公司（持 有上海凯利泰医疗科技股份有限公司 3.51%股份）提名，提 交股东大会审议，相关资料本人已提交承诺书，承诺真实 有效。 二、本人不存在《中华人民共和国公司法》第一百七 十八条等规定不得担任公司董事的情形。 ☑ 是 □ 否 如否，请详细说明：______________________________ 三、本人符合中国证监会《上市公司独立董事管理办 1 上海凯利泰医疗科技股 ...

上海凯利泰医疗科技股份有限公司独立董事提名人声明 提名人上海凯诚君泰投资有限公司现就提名刘学文为 上海凯利泰医疗科技股份有限公司第六届董事会独立董事 候选人发表公开声明。被提名人已书面同意作为上海凯利 泰医疗科技股份有限公司第六届董事会独立董事候选人 （参见该独立董事候选人声明）。本次提名是在充分了解 被提名人职业、学历、职称、详细的工作经历、全部兼职、 有无重大失信等不良记录等情况后作出的，本提名人认为 被提名人符合相关法律、行政法规、部门规章、规范性文 件和深圳证券交易所业务规则对独立董事候选人任职资格 及独立性的要求，具体声明并承诺如下事项： 一、被提名人已经通过公司第六届董事会提名委员会 资格审查， 提名人与被提名人不存在利害关系或者其他可 能影响独立履职情形的密切关系。 ☑ 是 □ 否 如否，请详细说明：______________________________ 1 三、被提名人符合中国证监会《上市公司独立董事管 理办法》和深圳证券交易所业务规则规定的独立董事任职 资格和条件。 ☑ 是 □ 否 如否，请详细说明：______________________________ 四、被提名人符合公司章程 ...

Revenue Performance - The company achieved a revenue of 984,518,762.54 yuan in 2024, representing a year-on-year growth of 2.96% [2] - Revenue from the medical device manufacturing segment was 559,409,042.90 yuan, accounting for 56.83% of total revenue, with a slight decline of 0.83% [2] - Revenue from medical device trading was 142,589,662.08 yuan, making up 14.48% of total revenue, down by 8.38% [2] - Revenue from instrument disinfection services increased by 21.88% to 260,737,788.23 yuan, representing 26.48% of total revenue [2] - Other business revenues totaled 21,782,269.33 yuan, down by 3.76% [2] Profitability Analysis - The net profit attributable to shareholders was -105,565,367.23 yuan, a significant decline of 193.80% compared to the previous year [3] - The major reasons for the loss included inventory write-downs of 16,913,000 yuan due to unsold stock and a fair value loss of 87,144,700 yuan on equity investments [3] - The non-recurring net profit was -65,305,422.66 yuan, down 205.93% year-on-year, indicating severe impacts on core business profitability [4] - Basic earnings per share turned negative at -0.1472 yuan, a drop of 193.76% from the previous year [5] - Non-recurring earnings per share also fell significantly, reflecting challenges in core operations [6] Expense Management - Sales expenses decreased by 18.28% to 158,992,708.83 yuan due to reduced market promotion costs following the procurement policy [7][8] - Management expenses increased by 18.95% to 192,042,349.26 yuan, primarily due to expansion-related costs in a subsidiary [9] - Financial expenses surged by 162.99% to 4,209,261.14 yuan, attributed to reduced interest income and exchange losses [10] - R&D expenses were reduced by 27.03% to 43,304,384.54 yuan, reflecting cost control measures in response to the procurement policy [11] Cash Flow Analysis - Operating cash inflow totaled 1,128,947,149.87 yuan, down 10.42% year-on-year, with a net cash flow from operating activities of 157,752,381.96 yuan, a decrease of 42.48% [13][14] - Investment cash inflow increased by 116.43% to 1,759,887,245.92 yuan, while cash outflow rose by 128.27% to 2,282,215,370.06 yuan, resulting in a net cash outflow of -522,328,124.14 yuan [13][15] - Financing cash inflow increased by 77.13% to 321,956,821.60 yuan, with a net cash flow from financing activities of 69,855,182.16 yuan, up 139.49% [13][16] Human Resources and R&D - The number of R&D personnel decreased by 13.46% to 90, with a decline in the proportion of R&D staff to 7.29% [12] - The educational background of R&D staff shifted, with an increase in bachelor's degree holders and a decrease in master's degree holders, potentially impacting innovation capabilities [12] Overall Assessment - The company faces multiple challenges, including significant net losses, fluctuating expenses, and cash flow volatility, necessitating strategic adjustments to enhance operational efficiency and risk management [21]

上海凯利泰医疗科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 上海凯利泰医疗科技股份有限公司（以下简称"凯利泰"或"公司"）于 全文，因年度报告工作期间工作量大，且公司编制年度报告相关文件的时间紧迫， 公司《2024 年年度报告》全文有部分内容有误，现对该部分内容予以更正，相 关内容如下： 一、"第四节 公司治理" 之"四、报告期内召开的年度股东大会和临时 股东大会的有关情况"之"1、本报告期股东大会情况"中： | 更正前： | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 会议届次 | 会议类型 | 投资者参与比例 | 召开日期 | 披露日 | | | | | 期 | 会议决议 | | | | | | | | | | | | 巨潮资讯网， | | | | | | | | | 《2023 年度 | | | | | 年度股东大会 | | 17.78% | | | | | | | 会 | | 日 | 日 | 告》（公 | | | | | | | | | 告 编 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海凯利泰医疗科技股份有限公司（以下简称"公司"）于 2025 年 5 月 13 日在巨潮资讯网（http://www.cninfo.com.cn）披露了《第六届董事会第七次会议 决议公告》（公告编号：2025-046），经公司事后复核，因发现部分内容需要更 正，具体如下（更正部分加粗表示）： 更正前： 公司拟继续聘任李元平先生担任公司的副总经理，财务总监，任期三年。 李元平先生简历如下： 李元平先生，1979 年 8 月出生，现任公司董事、副总经理、财务总监，中 国国籍，无境外居留权，本科学历，中国注册会计师。2003 年 7 月至 2005 年 1 月任职于中国石油天然气第一建设公司；2005 年 2 月至 2005 年 12 月任职于佛 山市昊正会计师事务所；2006 年 1 月至 2017 年 2 月任职于立信会计师事务所， 历任审计员、项目经理、业务经理、高级经理等职务。2017 年 2 月加入上海凯 利泰医疗科技股份有限公司任副总经理、财务总监。 李元平先生具备与岗位要求相适应的专业能力和工作经验，其 ...

证券代码：300326 证券简称：ST 凯利 公告编号：2025-047 上海凯利泰医疗科技股份有限公司 关于第六届董事会第七次会议决议公告的更正公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海凯利泰医疗科技股份有限公司（以下简称"公司"）于 2025 年 5 月 13 日在巨潮资讯网（http://www.cninfo.com.cn）披露了《第六届董事会第七次会议 决议公告》（公告编号：2025-046），经公司事后复核，因发现部分内容需要更 正，具体如下（更正部分加粗表示）： 更正前： 3、审议通过了《关于续聘李元平先生为公司副总经理、财务总监的议案》 公司拟继续聘任李元平先生担任公司的副总经理，财务总监，任期三年。 李元平先生简历如下： 本议案已经第六届董事会审计委员会第二次会议审议通过。 更正后： 3、审议通过了《关于续聘李元平先生为公司副总经理、财务总监的议案》 公司拟继续聘任李元平先生担任公司的副总经理，财务总监，任期三年。 李元平先生，1979 年 8 月出生，现任公司董事、副总经理、财务总监，中 国国籍，无境外居留权，本科学历，中国注 ...

Financial Performance - The net profit attributable to shareholders for 2024 was -105.5654 million RMB, a decrease of 193.80% year-on-year, while the net profit after deducting non-recurring gains and losses was -65.3054 million RMB, down 205.93% compared to the previous year[5]. - The company's operating revenue for 2024 was ¥984,518,762.54, representing a 2.96% increase compared to ¥956,259,537.45 in 2023[20]. - The cash flow from operating activities decreased by 42.48% to ¥157,752,381.96 in 2024 from ¥274,260,691.58 in 2023[20]. - The total assets at the end of 2024 were ¥3,350,848,951.38, a slight decrease of 0.09% from ¥3,354,004,114.33 at the end of 2023[20]. - The company reported a basic and diluted earnings per share of -¥0.1472 for 2024, compared to ¥0.1570 in 2023, marking a decline of 193.76%[20]. - The company's weighted average return on equity was -3.77% in 2024, down from 4.02% in 2023[20]. - The company's non-recurring losses impacted net profit attributable to shareholders by -40.26 million yuan, compared to a gain of 50.89 million yuan in the previous year[61]. Inventory and Impairment - The company recognized inventory impairment losses of 16.9130 million RMB due to changes in market demand and product updates, as well as a significant valuation fluctuation in equity investments, leading to a total profit reduction of 225.6240 million RMB for the year[6]. - The company has engaged a third-party evaluation agency to assess the fair value of long-term equity investments and other non-current financial assets, resulting in an impairment provision of 121.5663 million RMB[6]. - The company recognized inventory impairment of 16.91 million yuan and long-term equity investment impairment of 121.57 million yuan due to market demand changes and valuation fluctuations[61]. Market and Industry Trends - The orthopedic medical device industry in China is experiencing rapid growth, with a significant increase in domestic companies due to the entry of foreign firms and improved technology and management practices[33]. - The average price reduction for orthopedic trauma products in a centralized procurement initiative reached 88.65%, with specific products like the ordinary bone plate system seeing a drop from approximately ¥4683 to ¥606, a decrease of 87.05%[34][35]. - The centralized procurement for orthopedic spinal products resulted in an average price drop of 84%, indicating a significant impact on market pricing and competition[36]. - The implementation of centralized procurement policies is anticipated to reduce patient financial burdens and standardize medical practices, while also pushing smaller companies out of the market[38]. - The orthopedic industry is expected to see a concentration of market share among leading domestic companies, enhancing their competitive advantage[39]. Strategic Initiatives and Future Plans - The company plans to focus on product innovation and explore new materials and technologies to adapt to the changing market landscape and procurement policies[40]. - Cost control measures will be reinforced, including reducing labor costs and operational expenses, to maintain profitability amid declining margins[39][40]. - The company aims to enhance production efficiency and scale to lower production costs, ensuring competitiveness in a low-margin environment[39][40]. - The company plans to integrate existing sales channels and enhance collaboration across product lines to create a multi-brand sales network targeting hospital markets[127]. - International market expansion efforts will be intensified, leveraging overseas subsidiaries to penetrate various regions and enhance brand recognition among clinical practitioners[129]. Research and Development - R&D investment totaled 43.98 million yuan, a decrease of 27.12% year-on-year, accounting for 4.47% of current operating revenue, down 1.84 percentage points from the previous year[64]. - The company aims to strengthen its R&D focus on orthopedic minimally invasive surgical products to maintain a competitive edge in the market[64]. - The company is working on multiple R&D projects, including a new expandable interbody fusion device aimed at enhancing its spinal product line and obtaining FDA registration[83]. - The company plans to expand its trauma product line with new models of locking plates and screws, which are expected to enhance competitiveness in the market[83]. Governance and Management - The company has implemented a governance structure that complies with relevant laws and regulations, ensuring transparency and accountability in its operations[157]. - The company established a performance evaluation incentive system linking management compensation to business performance[164]. - The company continues to maintain a diverse board composition, which is essential for effective decision-making and corporate governance[182]. - The company is focusing on enhancing its management team with experienced professionals from various sectors[184]. - The leadership changes are expected to align with the company's long-term growth strategy and operational goals[184]. Risks and Challenges - The company is facing significant risks due to the drastic changes in the external financing environment and the comprehensive collection of orthopedic consumables[5]. - The company anticipates increased market competition in the orthopedic sector, necessitating timely product launches with higher technical content to maintain profit margins[140]. - The company faces inventory impairment risks as it transitions from a dealer stocking model to a production model based on market sales planning, necessitating improved inventory management to avoid excess stock[150]. - The company is exposed to regulatory and policy risks, including price reduction trends in medical devices due to national procurement policies, which may challenge its market competitiveness[145].

证券代码：300326 证券简称：ST 凯利 公告编号：2025-048 上海凯利泰医疗科技股份有限公司 关于《2024年年度报告》的更正公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 上海凯利泰医疗科技股份有限公司（以下简称"凯利泰"或"公司"）于 2025 年 4 月 30 日在巨潮资讯网（www.cninfo.com.cn）披露了《2024 年年度报告》 全文，因年度报告工作期间工作量大，且公司编制年度报告相关文件的时间紧迫， 公司《2024 年年度报告》全文有部分内容有误，现对该部分内容予以更正，相 关内容如下： | 会议届次 | 会议类型 | 投资者参与比例 | 召开日期 | 披露日期 | 会议决议 巨潮资讯网， | | --- | --- | --- | --- | --- | --- | | | | | | | 《2023 年度 | | 2023 年度股东大 | 年度股东大会 | 17.78% | 2024 年 05 月 22 | 2024 年 05 月 22 | 股东大会决议公 | | 会 | | | 日 | 日 | 告》（公 | | | ...

去年10月，中国人民银行牵头设立股票回购增持再贷款工具之后，上市公司增持积极性明显升高。数据显示，截至2025年4月末，上市公司披露拟申请股票 回购增持贷款金额上限超1100亿元。 7家公司6位高管增持超过千万股 从变动股份数量来看，有7家公司的6位高管增持股份数量超过千万股，包括山鹰国际总裁吴明武、星宇股份股东周晓萍、大中矿业总经理林圃生、豪能股份 董事向星星、龙迅股份董事FENG CHEN、陕西黑猫实控人李保平。 今年5月7日，中国人民银行再次宣布将证券、基金、保险公司互换便利5000亿元和股票回购增持再贷款3000亿元额度合并使用，总额度8000亿元，同时下调 结构性货币政策工具利率0.25个百分点，各类专项结构性货币政策工具利率降至1.5%。从资金灵活性、成本等多方面支持上市公司回购增持公司股票，进而 助力维护资本市场稳定运行，提振市场信心。 业内人士预计，未来上市公司增持将再现高潮。 派林生物增持次数最多 根据同花顺数据，今年1月有60家上市公司共进行增持，2月有48家上市公司共进行增持，3月有61家上市公司共进行增持，4月有54家上市公司共进行增持， 5月至今已有34家上市公司共进行了增持。 从增 ...